Molbio Diagnostics IPO: A High-Risk Bet on Long-Term Growth?
Molbio Diagnostics seeks ₹940 crore through IPO for capital expansion and promoter stake reduction.
Molbio Diagnostics, a prominent player in molecular diagnostics, is launching an initial public offering (IPO) aimed at raising ₹940 crore. This includes ₹200 crore through a fresh issue to bolster capital expenditure and ₹740 crore via an offer for sale, reducing the promoter group's stake from 46.6% to 43%.
Global Reach and Revenue Drivers
Founded in 2000, Molbio Diagnostics operates six manufacturing facilities across India and serves over 90 countries. The company is known for its 'Truenat' platform, a portable diagnostic system that provides rapid and accurate results, particularly in resource-limited settings. This technology is pivotal in the fight against tuberculosis, contributing to 70% of the company's test kit sales.
Molbio's client base includes government health programs and international healthcare organizations, which account for over 80% of its revenue. However, a significant portion of its revenue is concentrated among its top clients, raising potential concerns about customer concentration risks.
Financial Performance and Growth Prospects
Between FY24 and FY26, Molbio's revenue grew at an annual rate of 31.5%, reaching ₹1,445.7 crore, while net profit increased by 40.2% to ₹164.1 crore. The company's EBITDA rose by 33.2% to ₹328.2 crore, with the EBITDA margin improving to 22.6% in FY26 from 22% in FY24.
In FY26 alone, revenue saw a year-on-year increase of 41.7%, with EBITDA up by 27.9% and net profit by 18.4%. These figures underscore the company's robust growth trajectory, driven largely by its tuberculosis diagnostic test kits.
Market Valuation and Investor Considerations
Post-IPO, Molbio Diagnostics is seeking a price-earnings (P/E) multiple of up to 57. While it has no directly comparable listed peers in India, similar companies in the healthcare diagnostics and medical device sectors, such as Poly Medicure and Dr. Lal PathLabs, trade at P/E multiples ranging from 54 to 81.
Investors with a high-risk tolerance might find the IPO appealing due to Molbio's growth potential and its innovative diagnostic solutions. However, the reliance on a limited number of clients and the competitive landscape of the diagnostics industry present challenges that prospective investors should consider.